RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Monoamine reuptake inhibitors

Carroll, F., Blough, B., & Abraham, P. (2017). Monoamine reuptake inhibitors. (U.S. Patent No. 9,562,001). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,562,001.PN.&OS=PN/9,562,001&RS=PN/9,562,001

Abstract

The invention provides bupropion analog compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Meet the Experts

Navigate to Bruce Blough

Bruce Blough

Recent Publications

Article

Developing capacity in identifying cost-effective interventions to prevent and reduce obesity in China
Article

US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article

Comparing youth-friendly clinics to the standard of care for adolescent girls and young women in Malawi: A qualitative analysis
Article

Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial